Updated results from the multicenter phase II study of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC)-MedSci.cn

Updated results from the multicenter phase II study of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC)

Zhou, F; Wang, W; Xia, L; Dai, J; Wu, H; Yang, L; Gong, J; Chen, X; Xiong, Z; Liang, X

ANNALS OF ONCOLOGY, 2023; 34 (): S439

科室
- - 订阅+
  - 更多科室
工具
服务